| Date | Title | Description |
| 17.08.2026 | Arm Fat Overtakes All Other Concerns as Top Reason Singapore Women Seek Body Sculpting Consultations, Clinic Data Shows | Amaris B. Clinic’s first-half 2026 enquiry figures show arm-related concerns accounted for 41.4% of all body-sculpting enquiries from women, with nearly half of those enquiries coming from women in their 40s. Medical director, Dr Ivan Puah ... |
| 17.07.2026 | ReefHaven Ventures: UCSD Bioengineering Alumnus Garrett Smith Launches Fund Focused On San Diego MedTech Startups | Garrett Smith, a University of California San Diego bioengineering PhD alumnus, has launched ReefHaven Ventures as founding managing partner, a San Diego-focused venture capital fund dedicated to early-stage medical technology startups with... |
| 03.06.2026 | New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction | Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles. Results revealing no complications and high satisfaction prove the ne... |
| 20.04.2026 | Amazon ‘strong-armed’ Levi’s, Hanes to hike prices on rival sites, California AG says | California’s attorney general released a set of new, unredacted documents in its 2022 antitrust lawsuit against Amazon.
The documents detail internal communications between Amazon and major vendors, where it allegedly coerced them into conv... |
| 14.01.2026 | Landmark AbbVie-Trump Deal Reshapes Drug Access, Ignites U.S. Pharma Investment | A monumental three-year agreement reshapes pharmaceutical access. The Trump administration and AbbVie forged a new path. AbbVie will dramatically reduce drug prices within Medicaid. It will also expand direct-to-patient offerings through th... |
| 13.01.2026 | AbbVie And Trump Administration Strike $100 Billion Deal Tied To Medicaid Prices, Direct-To-Patient Drug Access, And U.S. Investment Plan | AbbVie announced it has reached a voluntary, three-year agreement with the Trump administration aimed at expanding access to medicines and lowering costs for Americans, while the company commits to a decade-long investment push in U.S. rese... |
| 01.01.2026 | Rising Through Challenge: Living Phoenix's 2026 New Year Message POGMENT Biomimetic Collagen | CHENGDU, China, Jan. 1, 2026 /PRNewswire/ -- As the Year of the Horse begins, bringing new momentum and promise, Living Phoenix—a pioneer in next-generation biomaterials—wishes all friends, partners, and users a joyful New Year.
May you sta... |
| 12.11.2025 | Moxie Announces Aesthetic Business Advisory Board and Scale Society Community to Shape the Next Era of Aesthetic Medicine | Moxie—the all-in-one growth and operating engine trusted by 600+ of the nation's fastest-growing aesthetic practices—today announced two major initiatives shaping the future of aesthetic entrepreneurship and bridge the business gap in aesth... |
| 26.03.2025 | CBC Group hits first close on China’s largest healthcare buyout fund | CBC Group has raised over RMB 7 billion (USD 980 million) in the first close of its inaugural RMB-denominated healthcare buyout fund, with a target size of RMB 10 billion (USD 1.4 billion). The fund, which is now the largest of its kind in ... |
| 13.12.2024 | Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases | Angitia Biopharmaceuticals – a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases – announced the closing of a $120 million Series C financing round. Bain ... |
| 29.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised To Increase Healthspan By Manipulating Thymus Functions | Tolerance Bio, a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, announced the closing of its ov... |
| 23.10.2024 | Horizon Surgical Systems: A New Dawn in Microsurgery | In the heart of Malibu, a revolution is brewing. Horizon Surgical Systems, a micro-robotics company, has secured $30 million in Series A funding. This isn’t just another investment; it’s a leap into the future of surgery. The funding round ... |
| 22.10.2024 | Horizon Surgical Systems: Micro-Robotics Company Raises $30 Million (Series A) | Horizon Surgical Systems, a privately held micro-robotics company advancing microsurgery with automated AI-enabled robotics, announced the closing of a $30 million Series A financing. The funding was led by ExSight Ventures and a major corp... |
| 20.10.2024 | Tolerance Bio: Pioneering the Future of Immune Health with $17.2 Million Seed Funding | In the world of biopharmaceuticals, innovation is the lifeblood. Tolerance Bio, a Philadelphia-based company, has just secured $17.2 million in seed funding. This financial boost is not just a number; it represents a beacon of hope for many... |
| 20.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised For Increasing Healthspan By Adjusting Function Of The Thymus | Tolerance Bio – a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the closing of its ... |
| 17.10.2024 | Mars Petcare's Leadership Shake-Up: A New Era for Veterinary Health and Diagnostics | In a bold move, Mars Petcare has reshuffled its leadership deck, signaling a fresh chapter for its Veterinary Health and Science & Diagnostics divisions. This change comes as the company, a titan in the pet care industry, seeks to innov... |
| 16.10.2024 | Mars announces new leadership for its Veterinary Health and Science & Diagnostics businesses | Nefertiti Greene announced as Global President of Mars Veterinary Health
Katie Devine joining to lead Mars Science & Diagnostics
Devine brings over 25 years' experience in consumer health and pharma
Mars has been a global leader in pet ... |
| 01.10.2024 | ADNOC to acquire German chemicals company Covestro for $16 bn | Abu Dhabi's ADNOC has struck a deal to buy German chemicals maker Covestro for 14.7 billion euros ($16.3 billion), including debt, in the energy giant's biggest ever acquisition.
The deal is one of the largest foreign takeovers by a Gulf st... |
| 18.06.2024 | Sinclair Poised for Expansion with Dr. Ryan Irvine at the Helm | Dr. Ryan Irvine
Sinclair, a global aesthetics leader, today announced the appointment of Dr. Ryan Irvine as its new Chief Development Officer. This strategic move underscores Sinclair's unwavering commitment to becoming the preeminent leade... |
| 04.06.2024 | Monthly people move spotlight: Jim Langston joins Paul Weiss' M&A group | figcaption>span]:font-sans">
Jim Langston joined Paul Weiss' M&A group after a nearly decade-long tenure at Cleary Gottlieb.
Why it matters: Paul Weiss did 139 deals worth $274 billion in 2023, and it booked $2 billion in rev... |
| 30.05.2024 | US, UK in focus as pharma companies eye $31 billion exports in FY25 | - |
| 23.05.2024 | Non-invasive filler alternatives for healthier-looking skin | - |
| 20.05.2024 | Philadelphia's Premier CoolSculpting Provider, Lux Skin & Lasers by John Lee, MD Recognized by Allergan as Top CoolSculpting Provider by Volume of Sales | Lux Skin & Lasers by John Lee, MD
Lux Skin & Lasers by John Lee, MD office achieves top ranking as Allergan recognizes them as #1 Philadelphia Region CoolSculpting Elite Provider for volume of treatments performed. The recognition h... |
| 06.05.2024 | Renowned Plastic Surgeon, Dr. Erez Dayan, Speaking at Upcoming October Symposium in Cape Town, South Africa | Dr. Erez Dayan
With an impressive background and a commitment to excellence, Dr. Erez Dayan is set to share his expertise and insights with esteemed symposium attendees.
RENO, Nev., May 6, 2024 /PRNewswire-PRWeb/ -- Dr. Erez Dayan has accep... |
| 21.04.2024 | Predicting the Next Breakthroughs in Eye Care Technology | - |
| 16.04.2024 | Counterfeit Botox blamed in 9-state outbreak of botulism-like illnesses | Biden administration investigating counterfeit botox injections in Florida, eight other states
Biden administration investigating counterfeit botox injections in Florida, eight other states 01:13
Dangerous counterfeit versions of botulinum ... |
| 12.04.2024 | Dr. Donath Recognized on Cincinnati's Top Doctors List in Cincinnati Magazine 13 Years in a Row | Dr. Alexander S. Donath, a renowned facial plastic surgeon in Cincinnati, was named a Cincinnati Top Doctor for the 13th consecutive year.
Celebrating Dr. Donath's 13-Year Streak as a Top Doctor
CINCINNATI, April 12, 2024 /PRNewswire-PRWeb/... |
| 21.03.2024 | More Middle-Aged and Older Men Are Seeking Male Breast Reduction In Singapore, says Dr Ivan Puah | The mean age of men seeking gynecomastia surgery at Amaris B. Clinic Singapore was 33. However, recent years have witnessed a notable increase in older male patients above 42, with the oldest being 70.
SINGAPORE, March 21, 2024 /PRNewswire/... |
| 13.03.2024 | Anxiety Disorder Treatment Market Size and Share Analysis, Trends, Advancements, Growth Forecast, 2030 | Anxiety Disorder Treatment Market
Anxiety Disorder Treatment Market to Reach $15.89 Billion by 2030, driven by the increasing prevalence of anxiety disorders & advancements in treatment options
With increasing awareness, growing prevale... |
| 12.03.2024 | Global Ophthalmic Eye Droppers Market Report 2024: A $25.88 Billion Opportunity by 2034 with Regional and Country-Level Data for Types, Drugs, Treatments, and End-users | - |
| 12.03.2024 | UDCA Market Insights and Forecast to 2032: Mechanism of Action, Regulatory Milestones, and Growth Forecast for PBC Treatment | - |
| 09.03.2024 | CVS Pharmacy to Settle for $10 Million for Alaska Opioid Crisis | March 8, 2024
(Anchorage, AK) – The State of Alaska filed a complaint and consent judgment Thursday against chain pharmacy CVS to close out the settlement process that began two years ago involving the opioid crisis in Alaska.
Once the se... |
| 05.03.2024 | Health | The new beauty regimen: Lose weight with Ozempic, tighten up with cosmetic surgery | Andrea Chang | Los Angeles Times (TNS)
LOS ANGELES — Jeniffer Brown wanted the Ozempic body. She just didn’t want “Ozempic face.”
She got both, dropping 20 pounds in the first four months after she started taking the blockbuster injectable ... |
| 04.03.2024 | Biopharmaceutical Innovations Lead the Way in Migraine Drugs Market Advancement | CAGR of 3.1% | Migraine is a clinical condition associated with painful headaches and other symptoms such as nausea, sensitivity to smell, and others.
PORTLAND, OREGON, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- Migraine drugs are medications that... |
| 21.01.2023 | Paxton Announces that Texas Has Joined $2.37 Billion Settlement With Opioid Manufacturer Allergan | Attorney General Paxton announced that Texas is joining a $2.37 billion settlement with opioid manufacturer Allergan for its role in the nationwide opioid epidemic. The agreement in principle was previously announced in July 2022. Under the... |
| 29.07.2022 | Attorney General Bonta Announces $2.37 Billion Nationwide Settlement with Former Opioid Manufacturer Allergan | If finalized, the Allergan settlement, together with the Teva settlement announced earlier this week, would provide as much as $6.6 billion nationwide to address the opioid epidemic
OAKLAND – California Attorney General Bonta today announce... |
| 29.07.2022 | July 29, 2022 - Attorney General Miyares Announces $2.37 Billion National Agreement With Former Opioid Maker Allergan | Commonwealth of Virginia
Office of the Attorney General
Jason S. Miyares
Attorney General
202 North 9th Street
Richmond, Virginia 23219
804-786-2071
FAX 804-786-1991
Virginia Relay Service
800-828-1120
For media inquiries only, contact:
Vic... |
| 10.01.2022 | Ironwood Pharmaceuticals : Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance - Form 8-K | Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
- LINZESS Expected to Achieve Blockbuster Status with U.S. Net Sales in Excess of $1 Billion in 2021 -
- Initiates Board Authori... |
| 04.11.2021 | Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update - Form 8-K | Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
- LINZESS® (Iinaclotide) prescription demand growth increased 12% year-over-year;
LINZESS U.S. net sales of $253 million, an increase of 5... |
| 17.03.2020 | Generic ‘identity’ gets lost when companies juggle both generic and brand drugs | We think we know generic drug companies. They challenge patents held by brand firms. They litigate vigorously to overturn those patents. And they often win these challenges.
But what about “generic” companies that play both sides, earning r... |
| 25.06.2019 | AbbVie to Acquire Allergan for Approx. $63 Billion | Biopharma giant AbbVie Inc. (NYSE: ABBV) is to acquire Allergan plc (NYSE: AGN), a Dublin, Ireland-based pharmaceutical company, for an equity value of approximately $63 billion.
The deal provides immediate scale and profitability to AbbVie... |
| 28.05.2019 | Mallinckrodt updates spin-off plans; FDA expands Vraylar approval for Allergan; Juvenescence spawns Souvien Therapeutics | → UK-based biopharmaceutical company Mallinckrodt $MNK — the maker of the controversial drug Acthar — has updated its plans for its new spin-off company, first announced last year. The new plan is to divide the company ... |
| 17.05.2019 | Allergan wins a novel case over false ads by a compounder, but gets just $48,500 for its trouble | In a closely watched case, Allergan (AGN) won a lawsuit in which it used a novel legal theory to blunt competition from a compounding pharmacy, although the victory came at a price.
Here’s the backstory: The drug maker accused Imprimis Phar... |
| 10.03.2019 | Clinical trials of Allergan’s antidepressant rapastinel fail | The three studies – RAP-MD-01, -02 and -03 – measured change over a three-week period in baseline measurements on the Montgomery-Asberg Depression Rating Scale, or MADRS, at the end of the study as their primary endpoints, according to Clin... |
| 07.08.2018 | Allergan picks up option for Editas' rare eye disease drug; CureGenetics bags $17M | → Allergan has stepped in to pick up its development option on Editas‘ experimental EDIT-101 for Leber congenital amaurosis type 10. And the smaller biotech is grabbing co-promotion rights as they look to a future ex... |
| 24.07.2018 | A new treatment for a condition that can feel like tiny people skating on razor blades in your stomach and affects an estimated 200 million women just got approved | Reuters
Instead of turning to surgery, drugmakers are hoping to treat diseases like uterine fibroids and endometriosis with new medications.
Advertisement
The FDA just approved elagolix, a new treatment for women living with endometriosis.
... |
| 15.06.2018 | Aimmune signs Jayson Dallas on to succeed retiring CEO; Eduardo Bravo leaves TiGenix in final chapter of Takeda buyout | → Ex-Ultragenyx commercial chief Jayson Dallas is taking the helm at Aimmune Therapeutics $AIMT — the company best known for its peanut allergy drug — well in time for a comfortable transition with the outgoing CEO, Steph... |
| 14.06.2018 | Sanofi sells manufacturing site to Recipharm; Aptose buys rights to sell CrystalGenomics' cancer drug in China | → Sanofi is selling off its contract respiratory drug manufacturing site in the UK to Recipharm, which is picking up manufacturing capacity as well as new clients in the $60 million deal. The plant’s 450 staffers will s... |
| 08.06.2018 | A handful of Allergan's top shareholders want to bring back the old CEO as chairman | REUTERS/Shannon Stapleton
Former Allergan CEO David Pyott.
Advertisement
A handful of large Allergan shareholders are privately discussing bringing back former Allergan CEO David Pyott in a chairman role, according to people familiar with t... |
| 27.04.2018 | Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant | Allergan $AGN rolled out its second wave of positive Phase III data for its oral migraine drug ubrogepant, which nailed its endpoints in the higher dose but failed to elicit much effect in the lower amount.
The drug was tested... |
| 20.04.2018 | 'Losing direction': Allergan investors are unhappy after a wild 4 hour takeover drama | Reuters
Allergan CEO Brent Saunders prepares to give an interview on the floor of the New York Stock Exchange (NYSE) April 6, 2016.
Advertisement
Allergan's stock closed down 4% on Thursday, after the pharma giant said it was "in the e... |
| 03.01.2018 | Two biotech startups receive milestone payments | |
| 13.11.2017 | Alnylam's patisiran grabs EMA accelerated review; CRISPR Therapeutics, Casebia enter mRNA deal with CureVac | → Promising Phase III data on patisiran have proven quite productive for Alnylam, which announced today that the EMA has granted an accelerated assessment for the hereditary ATTR amyloidosis treatment. The RNAi thera... |
| 11.10.2017 | Eye disease entrepreneurs raise $16M for Azura Ophthalmics | The founders of Azura have cut their teeth in the eye treatment sector. Dr. Yair Alster, founder and CTO, helped start ForSight Vision4. The company was created with ophthalmic incubator ForSight Labs and acquired by Roche-Genentech earlier... |
| 10.10.2017 | 'That should be illegal': Lawmakers are taking aim at pharma giant Allergan over an unusual deal with a Native American tribe | Reuters
Allergan CEO Brent Saunders prepares to give an interview on the floor of the New York Stock Exchange (NYSE) April 6, 2016.
Advertisement
In September, Allergan struck an unusual deal with the Saint Regis Mohawk Tribe to transfer pa... |
| 09.09.2017 | Allergan CEO gambles a multibillion-dollar franchise — and his company rep — on a high-stakes bet at an Indian casino op | Bioregnum — The view from Endpoints News
Allergan CEO Brent Saunders scored some heavyweight kudos last fall with a social contract that condemned predatory drug pricing by the likes of Martin Shkreli and outlined the compa... |
| 14.03.2017 | Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseases | Katrine Bosley, Editas. Credit: Jon Chomitz
Allergan is jumping into the CRISPR business.
The biotech struck a deal to partner with CRISPR/Cas9 leader Editas $EDIT on up to five programs aimed at curing eye diseases. And the... |
| 06.03.2017 | Allergan scores an FDA OK for a new drug targeting night-time urination | Allergan has scored a new drug approval. But don’t feel bad if you missed the news late last week. This has been a low-profile development effort with a long stretch in late-stage development.
Allergan signed a commercializa... |
| 09.01.2017 | Allergan bags two new deals, takes option to buy Lysosomal Therapeutics and pays $50M for microbiome pact | Kees Been
Allergan swooped into JP Morgan bearing news of a pair of deals, inking an exclusive option to buy out Lysosomal Therapeutics for its neurodegeneration pipeline and paying $50 million upfront to partner with... |
| 03.10.2016 | MedImmune out-licenses potential medicine for inflammatory diseases to Allergan | MedImmune out-licenses potential medicine for inflammatory diseases to Allergan
03-10-2016
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan p... |
| 21.09.2016 | Allergan Acquires Akarna Therapeutics, for $50M | Allergan plc., (NYSE: AGN), acquired Akarna Therapeutics Ltd., a Cambridge, UK-based biopharmaceutical company, for an upfront cash payment of $50m.
The deal also included success-based development, regulatory and sales milestones.
Under th... |
| 12.09.2016 | With small RetroSense deal, Allergan hoping for big win | RP is a group of congenital retinal diseases driven by mutations in the rhodopsin gene. The disease initially impacts retinal cells called rods, which provide peripheral and night vision. As the rods degenerate, neighboring cones, which all... |
| 06.09.2016 | Allergan CEO promises to limit price hikes on drugs in a bid to rebuild the ‘social contract’ | Seeking to deflect harsh criticism of the pharmaceutical industry, one chief executive officer — Allergan’s Brent Saunders — has taken the unusual step of promising to avoid “price gouging” and agreed to limit price hikes on brand-name medi... |
| 06.09.2016 | Allergan CEO Brent Saunders takes a pricing pledge: Predatory practices must end | Brent Saunders, Allergan
Caught in the latest tempest over dramatic price hikes for old therapeutics, Allergan CEO Brent Saunders is swearing off the practice, vowing to maintain a fair pricing policy that could well in... |
| 27.07.2016 | Schneider Electric Accelerates Renewable Energy Transactions, Connects Buyers with Developers and Technology Providers | Schneider Electric today introduced the New Energy Opportunities (NEO) Network™, a collaborative online platform that helps commercial and industrial companies quickly identify and vet renewable energy, cleantech and energy-efficiency prosp... |
| 22.04.2016 | Allergan Acquires Topokine Therapeutics, for $85M | Allergan plc (NYSE: AGN), a Dublin, Ireland-based pharmaceutical company, acquired Topokine Therapeutics, a Boston, MA-based clinical-stage biotechnology company, for an upfront payment of $85m.
The deal also includes success-based developm... |
| 06.04.2016 | Pfizer backs out of $160B Allergan deal; White House scores victory | The Treasury Department said Monday that new rules would limit companies’ ability to participate in inversion transactions if they’ve already done them within the past 36 months. Allergan has been involved in several such acquisitions in th... |
| 01.02.2016 | Awaiting approval for merger, Allergan touts economic impact study | In an unusual move, Allergan has touted a study detailing its many contributions to the economy in Waco, Texas, where the drug maker has a manufacturing facility. And the results could be used to bolster its case in Washington, D.C. for app... |
| 07.01.2016 | Allergan Acquires Anterios for $90M | Allergan plc (NYSE: AGN), a Dublin, Ireland-based global pharmaceutical company, acquired Anterios, Inc., a New York, NY-based clinical stage biopharmaceutical company developing a delivery system and botulinum toxin-based prescription prod... |
| 01.12.2015 | Allergan and New York settle suit over Alzheimer’s drug switching | Allergan and New York State have settled a heated antitrust lawsuit that accused the drug maker of switching patients from an older dementia pill to a newer and more expensive version in order to avoid generic competition. As part of the de... |
| 07.09.2015 | Allergan Buys AqueSys for $300M | Allergan plc (NYSE: AGN), a Dublin, Ireland-based global pharmaceutical company, is to acquire AqueSys, Inc. a Southern Californian clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure... |
| 27.07.2015 | Following Its $560M Acquisition, NU Drug Startup Naurex Launches New Research Company | This weekend Naurex, an Evanston-based biopharma company that creates depression-treating drugs, was acquired by Dublin-based pharmaceutical company Allergan for $560 million, plus success-based and sales-threshold milestone payments.
Aller... |
| 06.07.2015 | Allergan to Acquire Oculeve for $125M | Allergan plc (NYSE: AGN), a Dublin, Ireland-based global pharmaceutical company, is to acquire Oculeve, a South San Francisco, CA-based development-stage medical device company focused on developing novel treatments for dry eye disease, for... |
| 18.06.2015 | 3 billionaire tech industry leaders will build robots, Allergan will pay $2.1B for double chin eliminator Kythera (Morning Read) | “As we enter the data technology era, robotics will become a critical field that catalyzes technological breakthroughs in numerous sectors such as healthcare, public services, research and at home,” said Ma, whose Alibaba Group is about 32%... |
| 07.01.2014 | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | The six venture-backed spinouts include:
Baronova, a startup trying for weight loss devices that are both non-surgical and non-pharma. The company closed a $27.3 million Series C round in February 2013, which was led by Boston Scientific (B... |
| 09.07.2013 | CEO Insight: Allergan’s David Pyott on demonstrating value | By David Pyott
At the recent BIO Convention, Ernst & Young issued its annual biotechnology industry report Beyond Borders: Matters of Evidence. The report featured a survey of biotech CEOs (of companies under $500 million in revenue) an... |
| 02.07.2013 | CEO Insights: What does “Value” mean in healthcare? | By David Pyott
Most companies that provide a good or service widely profess “our customers are our highest priority.” That’s no surprise; without customers, you can’t be in business. But for those of us in the pharmaceutical, biotech and me... |
| 10.06.2013 | CEO Insight: Allergan’s David Pyott on the federal Sunshine Act | By David Pyott
One of the realities of federal laws in the United States is that the passage of legislation is not an end point, but merely a step in what can be a lengthy process as the law is translated into enabling regulations. No law m... |
| 24.10.2012 | Dermatology therapeutics firm is born with $21M series A round | Stephen Tullman, who was an executive chairman with Vicept, will be the chairman of Aclaris’ board. Tullman currently serves as CEO of Ceptaris Therapeutics and managing partner of NeXeption, a biotechnology management company that identifi... |
| 04.09.2012 | Botox maker Allergan expands R&D in U.S., defies outsourcing trend (and wrinkles) | The anti-aging market is set to grow to $274.5 billion by 2013, according to data attributed to BCC Research.
Allergan’s eye pharmaceutical division alone had $670 million in the second quarter of 2012, and its Botox and neuromodulator prod... |
| 21.08.2012 | Molecular Partners signs Billion Dollar Contract with Allergan | |
| 16.08.2011 | Allergan veteran to lead TearScience European business | Between 20 million and 30 million Americans suffer from dry eyes, according to market research from CBDM.T. The firm projects that the dry eye market will reach $2.4 billion by 2014. But dry eye products on the market consist mainly of drug... |
| 30.03.2011 | Dry eye drug from Inspire gets patent extension in Japan | Diquafosol tetrasodium, marketed as Diquas, was launched in December by Japan-based drug partner Santen Pharmaceutical Co. Inspire and Santen entered into an agreement in 1998 that gave Santen an exclusive license to develop and market Diqu... |
| 17.02.2011 | Allergan wins FDA approval for broader use of weight loss device | Allergan Inc.’s (NYSE:AGN) Lap-Band is now approved for use in less-obese patients.
The Food & Drug Administration approved the weight loss device for patients with a body mass index of at least 35, or a BMI greater than or equal to 30 ... |
| 26.01.2011 | Allergan slides on breast implant-cancer link | Shares of Allergan Inc. (NYSE:AGN) stock were down nearly 2 percent after a Food & Drug Administration review found that women with breast implants have a greater chance of contracting a rare form of cancer.
The federal watchdog agency ... |
| 15.09.2010 | Ohio to get $4M from national settlements with two drugmakers | “As a result of these improper marketing campaigns, the Medicaid program in Ohio was paying for drugs that had been prescribed for uses that were not approved,”
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vul... |
| 22.01.2010 | Health care tops VC funding in ’09: MedCity Morning Read, Jan. 22, 2010 | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 19.01.2010 | Allergan and Covidien renew Lap-Band co-promotion agreement | Covidien (NYSE:COV) and Allergan Inc. (NYSE:AGN) extended a deal that has Covidien promoting Allergan’s Lap-Band anti-obesity device to surgeons and physicians in the United States.
The two companies began their co-promotion efforts in Nove... |
| 23.10.2008 | BAROnova pulls in funds for weight-loss tech | Medical technology company BAROnova announced today that it brought in $7.5 million in a second round of funding led by pharmaceutical firm Allergan. It plans to use the money to continue developing a weight loss device called the TransPylo... |
| 20.09.2007 | Life sciences briefing: Thursday, Sept. 20, 2007 | Featured companies: Allergan, Athenahealth, Atria Genetics, Celera, Esprit Pharmaceuticals, Vida Diagnostics
(NOTE: This item was posted on Friday, 9/21/07. I’ve backdated its timestamp to preserve the chronological order of the briefings.)... |
| - | Dry eye drug from Inspire gets patent extension in Japan | Two dry eye therapy patents owned by Inspire Pharmaceuticals (NASDAQ:ISPH) have received extensions in Japan, which gives the drug Diquas patent protection until February 2023.
Raleigh, North Carolina-based Inspire disclosed in a securities... |
| - | Allergan veteran to lead TearScience European business | Medical device company TearScience has hired a former Allergan (NYSE:AGN) executive to spearhead European commercialization efforts for its novel dry eye treatment.
Deithart Reichardt is now senior vice president of the European region for ... |
| - | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | TheraNova is a San Francisco-based sandbox incubator and capital technology developer for medical devices. With one exception, all the ideas for technology are internally generated, CEO Dr. Daniel Burnett said. That’s led to all its medical... |
| - | Pfizer backs out of $160B Allergan deal; White House scores victory | We can chalk this up as a huge win for the Obama administration: Pfizer’s backed out of that historic $160 billion merger with Allergan, thanks to Washington toughening up on corporate inversions.
Pfizer announced last year that it planned ... |
| - | Health care tops VC funding in ’09: MedCity Morning Read, Jan. 22, 2010 | Image via Wikipedia
Highlights of the important and the interesting from the world of health care:
Health care tops VC funding in ’09: Now is the time to be a health care startup. For the first time on record, venture capital investment in ... |
| - | Dermatology therapeutics firm is born with $21M series A round | One year after Botox maker Allergan (NYSE:AGN) acquired his dermatology company, Vicept Therapeutics, a serial entrepreneur has reassembled his management team to develop a new set of dermatology therapeutics.
Dr. Neal Walker has formed Acl... |
| - | Eye disease entrepreneurs raise $16M for Azura Ophthalmics | Close-up of woman’s blue eye. High Technologies in the futuristic. : contact lens
Azura Ophthalmics, which is developing therapies to combat meibomian gland dysfunction (MGD), an underlying cause of dry eye disease, closed a $16 million Ser... |
| - | Botox maker Allergan expands R&D in U.S., defies outsourcing trend (and wrinkles) | The trend of outsourcing research and development work that spurred massive layoffs by pharmaceutical companies and the growth of the contract research organization industry doesn’t seem to be in Allergan’s (NYSE:AGN) playbook.
The drug and... |
| - | Ohio to get $4M from national settlements with two drugmakers | Ohio will receive a $4 million cut of national legal settlements with two drugmakers that allegedly promoted medications for unapproved uses.
Of that amount, about $2.3 million will head back to the federal government as reimbursement for O... |
| - | How open science and external innovation are transforming drug development | For nearly 70 years, the traditional drug development model has been one in which large pharmaceutical companies operate largely in-house: conducting all R&D, building their development pipeline, clearing regulatory hurdles, and bringin... |
